Advances in the study of small molecule antagonists of chemokine receptors as anti-asthma agents.
- Author:
Hai-jie JI
1
;
Jin-feng HU
;
Nai-hong CHEN
Author Information
1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Anti-Asthmatic Agents;
pharmacology;
therapeutic use;
Asthma;
drug therapy;
Heterocyclic Compounds;
pharmacology;
Humans;
Phenylurea Compounds;
therapeutic use;
Piperidines;
pharmacology;
therapeutic use;
Pyridazines;
pharmacology;
Receptors, CCR1;
antagonists & inhibitors;
Receptors, CCR3;
antagonists & inhibitors;
Receptors, CCR4;
antagonists & inhibitors;
Receptors, CXCR4;
antagonists & inhibitors;
Receptors, Chemokine;
antagonists & inhibitors
- From:
Acta Pharmaceutica Sinica
2011;46(11):1286-1290
- CountryChina
- Language:Chinese
-
Abstract:
Asthma is a chronic inflammatory respiratory disease accompanied with airway inflammation, airway remodeling and bronchial hyperresponsiveness. Chemokines are important for the recruitment of immune cells to the lung, which play an important role in the formation and development of asthma. Targeting the chemokine receptors to anti-inflammation and anti-asthma is a new strategy and some candidate drugs are discovered recently. This review is focused on the development of chemokine receptor antagonists for anti-asthma, which will promote the compound designations.
